- Home
- RNP vs COGT Comparison
RNP vs COGT Comparison
Compare RNP & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- COGT
- Stock Information
- Founded
- RNP 2003
- COGT 2014
- Country
- RNP United States
- COGT United States
- Employees
- RNP N/A
- COGT N/A
- Industry
- RNP Investment Managers
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- RNP Finance
- COGT Health Care
- Exchange
- RNP Nasdaq
- COGT Nasdaq
- Market Cap
- RNP 1.1B
- COGT 1.1B
- IPO Year
- RNP N/A
- COGT 2018
- Fundamental
- Price
- RNP $22.26
- COGT $13.05
- Analyst Decision
- RNP
- COGT Strong Buy
- Analyst Count
- RNP 0
- COGT 11
- Target Price
- RNP N/A
- COGT $21.20
- AVG Volume (30 Days)
- RNP 117.6K
- COGT 1.2M
- Earning Date
- RNP 01-01-0001
- COGT 08-05-2025
- Dividend Yield
- RNP 7.94%
- COGT N/A
- EPS Growth
- RNP N/A
- COGT N/A
- EPS
- RNP N/A
- COGT N/A
- Revenue
- RNP N/A
- COGT N/A
- Revenue This Year
- RNP N/A
- COGT N/A
- Revenue Next Year
- RNP N/A
- COGT N/A
- P/E Ratio
- RNP N/A
- COGT N/A
- Revenue Growth
- RNP N/A
- COGT N/A
- 52 Week Low
- RNP $15.52
- COGT $3.72
- 52 Week High
- RNP $21.27
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- RNP 51.35
- COGT 66.38
- Support Level
- RNP $21.96
- COGT $11.87
- Resistance Level
- RNP $22.55
- COGT $13.50
- Average True Range (ATR)
- RNP 0.24
- COGT 0.55
- MACD
- RNP 0.01
- COGT 0.05
- Stochastic Oscillator
- RNP 58.57
- COGT 77.16
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.